Cullinan Oncology, Inc. (CGEM)
NASDAQ: CGEM · IEX Real-Time Price · USD
18.45
+0.05 (0.30%)
Jul 22, 2024, 9:31 AM EDT - Market open
Cullinan Oncology Employees
Cullinan Oncology had 85 employees as of December 31, 2023. The number of employees increased by 23 or 37.10% compared to the previous year.
Employees
85
Change (1Y)
23
Growth (1Y)
37.10%
Revenue / Employee
n/a
Profits / Employee
-$1,557,035
Market Cap
1.05B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85 | 23 | 37.10% |
Dec 31, 2022 | 62 | 31 | 100.00% |
Dec 31, 2021 | 31 | 7 | 29.17% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Owens & Minor | 22,200 |
OPKO Health | 3,930 |
Silk Road Medical | 474 |
Ironwood Pharmaceuticals | 267 |
Calliditas Therapeutics AB (publ) | 217 |
Collegium Pharmaceutical | 197 |
Tango Therapeutics | 140 |
Innoviva | 112 |
CGEM News
- 7 weeks ago - Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement - GlobeNewsWire